These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 7648483

  • 1. Prevention of postmenopausal bone loss by rectal calcitonin.
    Reginster JY, Jupsin I, Deroisy R, Biquet I, Franchimont N, Franchimont P.
    Calcif Tissue Int; 1995 Jun; 56(6):539-42. PubMed ID: 7648483
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L.
    J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
    [Abstract] [Full Text] [Related]

  • 11. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 12. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.
    Kapetanos G, Symeonides PP, Dimitriou C, Karakatsanis K, Potoupnis M.
    Acta Orthop Scand Suppl; 1997 Oct; 275():108-11. PubMed ID: 9385282
    [Abstract] [Full Text] [Related]

  • 13. Salmon calcitonin in the prevention of bone loss at perimenopause.
    Arnala I, Saastamoinen J, Alhava EM.
    Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
    [Abstract] [Full Text] [Related]

  • 14. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 15. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX, Li H.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1280-4. PubMed ID: 18713548
    [Abstract] [Full Text] [Related]

  • 16. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW, Yeung SS.
    J Clin Endocrinol Metab; 1996 Mar 20; 81(3):1232-6. PubMed ID: 8772604
    [Abstract] [Full Text] [Related]

  • 17. Nasal calcitonin for treatment of established osteoporosis.
    Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS.
    Clin Endocrinol (Oxf); 1989 Apr 20; 30(4):435-42. PubMed ID: 2688995
    [Abstract] [Full Text] [Related]

  • 18. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
    Colpan L, Gur A, Cevik R, Nas K, Sarac AJ.
    Maturitas; 2005 Jul 16; 51(3):246-53. PubMed ID: 15978968
    [Abstract] [Full Text] [Related]

  • 19. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.
    Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P.
    Eur J Clin Invest; 1994 Aug 16; 24(8):565-9. PubMed ID: 7982445
    [Abstract] [Full Text] [Related]

  • 20. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.
    Body JJ.
    Bone; 2002 May 16; 30(5 Suppl):75S-79S. PubMed ID: 12008163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.